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1. Introduction 
Cachexia, the main cause of death in cancer 
patients, is a terminal metabolic condition which starts 
with a negative nitrogen balance and weight loss and 
continues until it reaches its final characteristic clini- 
cal picture. This process is usually quite fast in devel- 
opment. This progressive condition is likely to be the 
result of the metabolic interaction between the 
tumour and its host, an area that has generally received 
little attention compared with other aspects of 
tumour-host interactions. In order to understand 
this metabolic tumour-host interaction, we need to 
know the tumour requirements both for energy and 
for essential nutrients. Data has become available for 
a mammalian cell, a line of ascites carcinoma [ 11. I 
have applied these data in a model situation. The 
tumour requirements for energy and leucine are 
examined in the light of the daily exogenous require- 
ments of the host, estimated by the requirements of 
the average man as reported by FAO/WHO [2]. I reach 
the conclusion that a fast growing tumour increases 
significantly the leucine requirements of the host, 
without having an effect on the energy needs. 
2. Effect on energy requirements 
Malignant tumours are heavily dependent on the 
anaerobic utilization of glucose under aerobic condi- 
tions, aerobic glycolysis, as the main energy source 
[3]. The more malignant the tumour is, the more 
dependent it is on aerobic glycolysis [3]. Ascites cells, 
a highly malignant tumour, use glucose at 2 pm01 . 
min-’ . g cells-‘; 90% of this glucose is converted into 
lactate and provides 80% of the total energy produc- 
tion by the tumour [I], the remaining coming from 
glutamine oxidation. If the lactate is reconverted into 
glucose by the host liver, it would represent an expen- 
diture of 2 mol ATP . mol recycled glucose-‘, and the 
tumour would be acting as an ATPase. This extra 
expenditure of energy represents a <OS% increase in 
the daily energy requirement of the host, 2500 kcal . 
day-’ [2], even if the tumour size is 200 g (fig.1). 
The alternative possibility, that lactate is oxidised 
peripherally by the host, would represent only a 
slightly less efficient use of carbohydrates, but still 
would account for <l% of the daily energy supply. 
Probably in the host, lactate follows both fates. These 
data suggest hat the tumour, even if it is a fast grow- 
ing one, is not an energy drain on the host in a direct 
way, that is, as a consequence of the tumour needs. 
3. Effect on leucine requirement 
The effect of the tumour on the organism’s leucine 
requirement can be seen by reference to its effect on 
the daily intake of leucine for the host. The recom- 
mended daily intake is 1 .l g leucine . day-’ [2]. That 
recommended level is twice the actual need, though 
the leucine used by the tumour is of both exogenous 
and endogenous origin. In fig.1, we can see that there 
is a very significant increase in the exogenous intake 
of leucine as tumour size increases. The rate of leucine 
utilization by the tumour is 30 nmol . min-’ . g cells-’ 
[ 11; this value is the net incorporation of leucine into 
proteins and lipids once a balance between synthesis 
and degradation has been achieved. It represents the 
use of leucine by a heterogeneous population of 
tumour cells, as they are in the animal. This rate 
makes the tumour a drain on the leucine sources, and 
the consequent deprivation for the host of an essen- 
tial amino acid leads to the waste of other amino 
acids and to the net loss of less-vital proteins in the 
organism, either by stopping their synthesis or by 
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Fig.1. Effect of tumour on the daily intake of leucine (0) and 
energy (0). The reference values are the recommended aily 
intake of the host in the absence of tumour, according to 
FAO/WHO [ 21. For the energy calculations, it is assumed 
that lactate produced by tumour cells isrecycled by the host’s 
liver. One gram of cells is equivalent o -3.5 X lo9 cells. 
degradation as a compensatory effect. In experimental 
tumour bearing animals, a net uptake of essential 
amino acids has been observed by measuring the 
arterio-venous difference in amino acid concentra- 
tion in the hind leg bearing the tumour, but no corre- 
lation with tumour size, number of cells or rate of 
growth was made [4]. 
Two groups [5,6] have observed that in tumour 
bearing animals there was a significant decrease in the 
rate of protein synthesis in muscle. There was also a 
slightly increased rate of protein synthesis in liver, 
probably as a result of this organ’s role in general 
homeostasis, which may increase the demands made 
on other tissues to supply amino acids. A drop in pro- 
tein synthesis in muscle is also observed as a result of 
protein starvation [7]. The mechanism by which a 
decrease in protein synthesis is induced in peripheral 
tissues, mainly muscle, as a result of dietary manipu- 
lations or by increased overall requirements due to 
the tumour seems to be the consequence of essential 
amino acid deprivation leading to uncharged tRNA 
[8]. Nevertheless, during the initial stages of the 
tumour, this drainage can be easily overshadowed by 
several factors like age, sex, physical activity, weight, 
quantity and quality of the diet and perhaps the 
timing of food intake,efficiency of nutrient utilization 
and other particular tumour effects, though the effects 
of these factors may be very variable. Despite all 
these factors, a recent and very carefully controlled 
clinical study [9] clearly points to a problem of pro- 
tein starvation rather than an energy one in cancer 
patients. 
4. Amino acid pools and the preferential use 
of leucine 
One question that stands out is, why does the 
tumour not suffer a drop in the rate of protein syn- 
thesis if it is the subject of the same regulatory mech- 
anisms as normal cells [8]. This focuses the problem 
on the preferential use of nutrients by a particular 
group of cells. The metabolic conditions in a tumour 
may be similar to those in normal situations in which 
there is a group of cells under rapid proliferation, for 
example pregnancy [lo], and the healing period after 
surgery [ 11,121. In both cases, a negative nitrogen 
balance can easily be achieved. In tumours, there is a 
switch to a foetal isoenzyme pattern; this may be 
partly responsible for the appearance in tumour tissues 
of metabolic characteristics imilar to those in the 
embryo [13]. 
The selective use of nutrients can be the result of 
the characteristics of different amino acid pools in 
the organism and the interactions of these pools. 
Tumours and other fast growing cells are characterized 
by having a very small free leucine pool, and by having 
a very high utilization of this pool by each unit of 
mass of cells, in such a way that its use results in a net 
loss of leucine in the organism. This loss occurs either 
by incorporation of the leucine in lipids or in pro- 
teins. Despite the fact that the protein is a mobile 
pool, in practical terms of leucine availability to the 
host, this incorporation can be regarded as a net loss, 
consequent on the growth of the tumour. Because of 
this net loss, the intracellular pool is depleted. This 
creates within the cell a net flux towards protein/lipids, 
and if no exogenous supply is made available, this 
flux would lead to a sharp fall in the intracellular con- 
centration of the amino acid. However, the free intra- 
cellular amino acid pool is in contact with the pool in 
plasma, which is also small, and as a consequence of 
this contact, a concentration gradient is generated 
towards the inside of the cell. This might help the 
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active transport system, resulting in a net uptake [4] 
of the amino acid by the cell. From the data given in 
fig.1, we can see that a 100 g tumour would com- 
pletely deplete the plasma of leucine in -15 h. The 
plasma level can be maintained either from the exoge- 
nous supply from the diet, or from muscle. More than 
50% of the total free amino acid pool of the organism 
is contained in muscle, with an intracellular concen- 
tration higher than that in plasma. The use of the 
muscle amino acid pool per unit of mass is very low 
[ 141. The consequence of this is that muscle com- 
prises a large reservoir that can be mobilized by the 
demands of other groups of cells that have an effect 
on the plasma levels. Thus, we have a situation in 
which the equilibrium between the muscle and plasma 
pools can be altered, generating a net flux of leucine 
towards the plasma. This net outward flux of the 
amino acid from muscle has been observed during 
daily periods of fasting in man [ 141. It is highly likely 
that it also occurs in a case such as this, where there is 
an increased demand for nutrients due to the tumour 
requirements. We must remember that leucine is car- 
ried by the system L of amino acid transport which 
operates very well in an outward direction [ 15 ,161, 
and furthermore is able to carry most of the essential 
amino acids. 
We can summarize the situation by saying that a 
concentration gradient between the free amino acid 
pools is created with a net flux towards the cell which 
is causing a net loss of leucine (muscle --f plasma -+ 
tumour cell). This is a simplified explanation that can 
account for the phenomena of negative nitrogen 
balance, wasting of muscle, and weight loss observed. 
However, elucidation of the mechanism accounting 
for these phenomena, if correct, will have to await a 
better understanding of the regulation of amino acid 
pools and their interactions, of the regulation of 
active transport systems by modification of amino 
acid concentrations, and of the amino acid ratios on 
either side of the cell membrane. 
5. Conclusion 
A tumour characterized by rapid growth increases 
significantly the host requirement for leucine, while 
having no effect on the overall energy requirement. 
This situation may be one of the factors responsible 
for cachexia in cancer patients and can be explained 
as a result of the interaction between different amino 
acid pools in the tumour bearing animal. A better 
knowledge of the metabolic interaction between a 
tumour and its host will be possible when data for’ the 
requirements of human tumours become available, 
and as these requirements are examined within the 
framework of the tumour-host relationship, both 
theoretically and experimentally. This knowledge, 
when available, may be of use in the management of 
cancer patients. 
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